Efficacy of subsequent chemotherapy after progression of BRCA-mutated recurrent EOC progressing on olaparib versus placebo maintenance

The multinational SOLO2 study randomized patients with recurrent BRCA-mutated epithelial ovarian cancer (EOC) and response on platinum-based chemotherapy to maintenance treatment with olaparib or placebo. The progression-free survival was significantly improved with olaparib. A post-hoc analysis of efficacy of subsequent chemotherapy after progression on maintenance treatment in the study has now been published. The analysis found that with platinum-based chemotherapy the time to next progression was significantly longer in the placebo group compared to the olaparib group. This was not seen with non-platinum-based chemotherapy. The authors conclude that following progression from maintenance olaparib the efficacy of platinum-based subsequent chemotherapy seemed to be reduced.